Phase III IMvigor010: Adjuvant Atezolizumab vs Observation in Patients With High-Risk Muscle-Invasive Urothelial Cancer

May 29-31, 2020; Online at meetings.asco.org/am
Adjuvant atezolizumab did not improve disease-free survival in patients with high-risk muscle-invasive urothelial carcinoma compared with observation.
Format: Microsoft PowerPoint (.ppt)
File Size: 253 KB
Released: June 8, 2020

Acknowledgements

Provided by Clinical Care Options, LLC.

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
AstraZeneca
Bayer HealthCare Pharmaceuticals Inc.
Bristol-Myers Squibb
Exelixis
Pfizer and EMD Serono, Inc.

Related Content

In this slideset from Clinical Care Options, experts provide insights on the optimal use of CAR T-cell therapy for ALL

Renier J. Brentjens, MD, PhD Released: December 3, 2020

In this slideset from Clinical Care Options, experts provide insights on the optimal use of CAR T-cell therapy for lymphomas

Frederick L. Locke, MD Released: December 3, 2020

In this slideset from Clinical Care Options, experts provide insights on emerging CAR T-cell strategies for myeloma.

Noopur Raje, MD Released: December 3, 2020

Downloadable slides on current treatment landscape of patients with ovarian cancer from Clinical Care Options (CCO)

Bradley J. Monk, MD, FACS, FACOG Released: December 3, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue